Procizumab - 4TEEN4 Pharmaceuticals
Alternative Names: AK-1967Latest Information Update: 27 Feb 2025
At a glance
- Originator 4TEEN4 Pharmaceuticals
- Class Cardiovascular therapies; Monoclonal antibodies
- Mechanism of Action DPP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cardiogenic shock
Most Recent Events
- 18 Feb 2025 4TEEN4 Pharmaceuticals plans a phase Ib/II trial for Cardiogenic shock (Parenteral) in April 2025 (NCT06832722) (EUCT2024-518450-16-00)
- 04 Sep 2024 4TEEN4 Pharmaceuticals completes a phase I trial in Cardiogenic shock (In volunteers) in Netherlands (IV) (NCT06331884)
- 28 Mar 2024 Pharmacodynamics and adverse events data from preclinical trials in Cardiogenic shock released by 4TEEN4 Pharmaceuticals (4TEEN4 Pharmaceuticals website, March 2024)